Some US biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs watchdog under the Trump ...

"We believe our achievements from this past quarter, including capacity expansion and additional global approvals, are setting the stage for Legend Biotech ... for Medicinal Products for Human ...

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...